Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491346 | 0.83 | OPRL1 (0.43) | OPRD1OPRL1OPRM1OPRK1OGA | |
| SCHEMBL1738687 | 0.81 | OGA (0.36) | OPRD1OPRL1OPRM1OPRK1CHRNB2 | |
| SCHEMBL13543769 | 0.81 | PIK3CA (0.42) | OPRD1OPRM1ALDH1A1LMNAOGA | |
| SCHEMBL12488846 | 0.80 | ALDH1A1 (0.45) | OPRD1OPRL1OPRM1OPRK1POLB | |
| SCHEMBL19482468 | 0.80 | HRH3 (0.38) | CHRNB2CHRNA4OGAMEN1KMT2A | |
| SCHEMBL19491058 | 0.79 | OPRL1 (0.40) | OPRD1OPRL1OPRM1OPRK1OGA | |
| SCHEMBL19491059 | 0.79 | OPRL1 (0.40) | OPRD1OPRL1OPRM1OPRK1OGA | |
| SCHEMBL19491060 | 0.79 | OPRL1 (0.40) | OPRD1OPRL1OPRM1OPRK1OGA | |
| SCHEMBL10028305 | 0.78 | OPRL1 (0.46) | OPRD1OPRL1OPRM1OPRK1POLB | |
| SCHEMBL23425725 | 0.78 | OGA (0.32) | OPRD1OPRL1OPRM1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | OPRD1 657/4885OPRL1 1796/4885OPRM1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.